Stellar Biotechnologies Appoints Daniel E. Morse, Ph. D., Director and VP
Port Hueneme, CA - April 28, 2010, Stellar Biotechnologies, Inc. (OTC: SBOTF, TSX-V: KLH) has appointed eminent scientist Daniel E. Morse, Ph. D. as Director and Executive VP: Science & Technology effective April 19, 2010.
Stellar’s CEO, Frank Oakes, said, “Stellar is excited to have a scientist of Dr. Morse’s caliber leading its scientific and technical development. He brings a unique combination of world-renown expertise in the fields of molecular genetics, protein biochemistry, and the molecular processes controlling reproduction and development in molluscs, including the keyhole limpet, the source of our leading product, KLH. His pioneering work with the KLH molecule has helped identify a variety of new uses for our products and magnify his qualifications as an important addition to the Stellar team. We are honored that Stellar is the first public company for which Dr. Morse has agreed to become, a director, and also an executive.” http://www.lifesci.ucsb.edu/mcdb/faculty/morse/research/research.html
Dr. Morse is Professor of Molecular Genetics and Biochemistry at UCSB; he received his B.A. degree in Biochemistry from Harvard, and Ph.D. in Molecular Biology from Albert Einstein College of Medicine. He was awarded a Career Development Award from the National Institutes of Health and a Faculty Research Award from the American Cancer Society; honored as a Distinguished Faculty Scholar by the Woods Hole Oceanographic Institution, and as a Visiting Lecturer in Japan and the University of Paris; elected a Regents Fellow of the Smithsonian Institution; and elected a Fellow of the American Association for the Advancement of Science. Scientific American named him one of 50 leading technology pioneers of 2006 for his research on biologically inspired routes to nanostructured semiconductor thin films. He was honored as the 7th Kelly Lecturer in Materials and Chemistry by Cambridge and as the 3M Lecturer in Chemistry and Materials by the University of Vancouver. Dr. Morse is Director of the U.S. Army-sponsored UCSB-MIT-Caltech Institute for Collaborative Biotechnologies. http://www.c2c.ucsb.edu/summit2008/bio_dan_morse.php
Dr. Morse said, “I’m excited to be part of the dynamic growth we visualize for Stellar Biotechnologies and to continue my collaborations with their CEO, Frank Oakes, with whom I’ve worked for more than 20 years. The KLH molecule is unique because it is a potent booster of the immune system with a record of complete safety in humans for more than 45 years. In addition to its use as an effective and safe molecular carrier for numerous cancer vaccines now under development in the U.S. and abroad, and vaccines against many other diseases, it provides a safe and reliable quantitative measure of the health of the immune system and the readiness of patients for new transplantation and tissue-engineering therapies. My contributions to Stellar’s pioneering work with the keyhole limpet helped develop techniques for the precise control of reproduction and development in this valuable resource species, underpinning Stellar’s unique position as the only company world-wide to produce KLH from its own secure and renewable populations of aquaculture-raised animals, rather than from reliance on a dwindling supply of animals from the wild.”
Darrell Brookstein, VP
858 449 2523
About Stellar Biotechnologies, Inc (TSX-V: KLH): Stellar’s product, KLH, is a potent immuno-stimulatory protein with an exceptional record of safety and non-toxicity in humans that is being used in medicines known as conjugate therapeutic vaccines and in other biomedical products. Already a world leader in the production of KLH, Stellar plans to further monetize its KLH production platform and maximize the commercial impact of its intellectual property portfolio through the physical sourcing, purification and supply of medical-grade KLH. KLH is exclusively sourced from the blood of the rare keyhole limpet and Stellar has technology for the maintenance of that animal, as well as a non-lethal extraction method of the critical molecule and refinement process for KLH that it currently sells into growing academic, research, pharmaceutical markets.
Statements in this press release other than purely historical factual information, including statements relating to revenues or profits, or the Company's future plans and objectives, or expected sales, cash flows, and capital expenditures constitute forward-looking statements. Forward-looking statements are based on numerous assumptions and are subject to all of the risks and uncertainties inherent in the Company's business, including risks inherent in the technology history. There can be no assurance that such forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on such statements. Except in accordance with applicable securities laws, the Company expressly disclaims any obligation to update any forward-looking statements or forward-looking statements that are incorporated by reference herein. This news release does not constitute an offer to sell, or a solicitation of an offer to buy any of the Company's securities set out herein in the United States, or to, or for the benefit or account of, a U.S. Person or person in the United States.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.